Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?

Table 7 Characteristics, median survival, comparative study of patients (first and second cohorts) with an objective radiologic response in both ART ‘groups before the second TACE (%)

Patients with radiologic response	ART (0-1.5)(n = 113)	ART≥2.5(n =28)	P value
AFP < 200 ng/mL	81	82	1.00
AFP ≥ 200 ng/mL	19	18
Child-Pugh A/B	77/23	61/39	0.05
BCLC A/B/C	55/41/4	50/42/8	0.14
Median TACE sessions (95%CI)	3 (3-4)	2 (1-5)	0.17
Median-survival, mo (95%CI)	33 (27-38)	28 (13-35)	0.04
Median follow-up, mo (95%CI)	25 (22-29)	21 (13-31)	0.42

BCLC: Barcelona Clinic Liver Cancer; TACE: Transarterial chemoembolization.